Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dextran 40 reduces heparin-mediated platelet aggregation.

M Sobel, B Adelman, L J Greenfield

    The Journal of Surgical Research
    |April 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Contralateral reperfusion injury after carotid endarterectomy.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
    Same author

    Current treatment and prevention of pulmonary embolus with the greenfield filter.

    Surgical technology international·2015
    Same author

    Venous thrombosis incidence in burn patients: preliminary results of a prospective study.

    The Journal of burn care & rehabilitation·2002
    Same author

    Computed tomographic venography is specific but not sensitive for diagnosis of acute lower-extremity deep venous thrombosis in patients with suspected pulmonary embolus.

    Journal of vascular surgery·2001
    Same author

    Burnout among American surgeons.

    Surgery·2001
    Same author

    Renal artery aneurysms: a 35-year clinical experience with 252 aneurysms in 168 patients.

    Annals of surgery·2001
    Same journal

    Emergency Surgical Cricothyrotomy Videos Online: Reliability and Training Quality Evaluation.

    The Journal of surgical research·2026
    Same journal

    Management of Concomitant Traumatic Abdominal Vascular and Gastrointestinal Injuries: A Descriptive Study.

    The Journal of surgical research·2026
    Same journal

    Article Processing Charges in General Surgery Journals: Implications for Equitable Publishing Access in Low-Income and Middle-Income Countries.

    The Journal of surgical research·2026
    Same journal

    Association of Distal Internal Carotid Artery Tortuosity With Carotid Artery Stenting Outcomes.

    The Journal of surgical research·2026
    Same journal

    Appendectomy and Subsequent Type 2 Diabetes - A National Cohort study.

    The Journal of surgical research·2026
    Same journal

    Perceptions and Barriers to Intraoperative Non-technical Skills Feedback in General Surgery: A Mixed-Methods Study.

    The Journal of surgical research·2026
    See all related articles

    Dextran 40 selectively inhibits heparin-induced platelet aggregation in vitro, a key feature of heparin-associated thrombocytopenia (HAT). This finding suggests dextran as a potential treatment for HAT, without affecting heparin

    Area of Science:

    • Hematology
    • Pharmacology

    Background:

    • Heparin-associated thrombocytopenia (HAT) is a serious complication of heparin therapy.
    • HAT involves heparin-mediated platelet aggregation due to a specific plasma factor.

    Purpose of the Study:

    • To investigate the in vitro efficacy of Dextran 40 in reducing heparin-induced platelet aggregation in HAT.
    • To evaluate Dextran 40's selectivity in inhibiting heparin-mediated aggregation compared to ADP-stimulated aggregation.

    Main Methods:

    • Platelet aggregometry was used to assess platelet aggregation.
    • Experiments involved mixtures of normal platelet-rich plasma and HAT patient plasma.
    • Dextran 40 concentration was maintained at 2% (20 mg/ml).

    Main Results:

    Related Experiment Videos

    • Dextran 40 significantly reduced heparin-stimulated platelet aggregation by 60.5% in HAT plasma mixtures (P < 0.005).
    • Dextran 40 showed minimal inhibition (18.6%) of ADP-stimulated platelet aggregation.
    • Dextran 40 did not affect heparin's anticoagulant properties, unlike protamine.

    Conclusions:

    • Dextran 40 selectively inhibits heparin-mediated platelet aggregation in vitro.
    • This selective inhibition may occur by blocking heparin binding to platelet membranes.
    • Dextran 40 shows promise as a potential adjunctive therapy for heparin-associated thrombocytopenia.